Cerity Partners
NVCR icon

Cerity Partners’s NovoCure NVCR Stock Holding History

Cerity Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Buy
+28,739
New +$435K ﹤0.01% 2520
2024
Q3 		– Sell
-10,377
Closed -$178K – 2582
2024
Q2 		$178K Buy
+10,377
New +$182K ﹤0.01% 2046

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Cerity Partners's NVCR Position: Q2 2026 in Review

Cerity Partners opened a new position in NovoCure (NVCR) in Q2 2026: 28,739 shares worth $435K. The stake represents ﹤0.01% of the portfolio and ranks #2520 among its holdings. This is a return to the name: Cerity Partners previously reported a position in NVCR as recently as Q2 2024.

Cerity Partners first reported a position in NVCR in Q2 2024 and has held it in 2 quarters since. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Cerity Partners held 28,739 shares of NovoCure worth $435K as of Q2 2026.
  • NovoCure was a new Cerity Partners position in Q2 2026.
  • NovoCure made up ﹤0.01% of Cerity Partners's portfolio in Q2 2026, its #2520 holding.
  • Cerity Partners first reported a position in NovoCure in Q2 2024 and has held it in 2 quarters since.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Cerity Partners's 13F filing for Q2 2026, filed 14 Aug 2026.